Why the study?
Although DCN1 is recognized as an important therapeutic target for human diseases, its role in the cardiovascular area remains unknown.
Population
Ang II-treated isolated cardiac fibroblasts and mouse hearts after pressure overload
Comparison
DCN1-UBC12 inhibitor compound DN-2 evaluation
Design
Preclinical in vitro and in vivo molecular study
Authors
Loading...
Positions DCN1-UBC12 inhibition as a candidate antifibrotic approach; leaves open its efficacy in human cardiovascular disease.
The discovery of DN-2 as a DCN1-UBC12 inhibitor identifies DCN1 as a potentially novel therapeutic target for preventing cardiac fibrosis.
He et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: